35,000 Shares in Danaher Corporation (NYSE:DHR) Purchased by Pacific Capital Partners Ltd

Pacific Capital Partners Ltd acquired a new position in shares of Danaher Corporation (NYSE:DHR) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 35,000 shares of the conglomerate’s stock, valued at approximately $7,175,000. Danaher makes up approximately 4.5% of Pacific Capital Partners Ltd’s holdings, making the stock its 7th biggest position.

Other hedge funds have also modified their holdings of the company. FAS Wealth Partners Inc. grew its holdings in shares of Danaher by 20.6% during the fourth quarter. FAS Wealth Partners Inc. now owns 9,597 shares of the conglomerate’s stock worth $2,203,000 after buying an additional 1,639 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Danaher by 11.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,677,032 shares of the conglomerate’s stock worth $1,303,163,000 after buying an additional 579,046 shares in the last quarter. Rathbones Group PLC boosted its position in Danaher by 2.5% during the fourth quarter. Rathbones Group PLC now owns 319,502 shares of the conglomerate’s stock valued at $73,342,000 after purchasing an additional 7,695 shares during the last quarter. Soros Fund Management LLC acquired a new position in Danaher during the fourth quarter valued at approximately $29,950,000. Finally, NorthRock Partners LLC boosted its position in Danaher by 129.7% during the fourth quarter. NorthRock Partners LLC now owns 8,323 shares of the conglomerate’s stock valued at $1,910,000 after purchasing an additional 4,700 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Danaher news, Chairman Steven M. Rales sold 1,250,000 shares of the firm’s stock in a transaction on Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the transaction, the chairman owned 3,105,808 shares in the company, valued at $611,036,665.92. This trade represents a 28.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 11.20% of the stock is currently owned by company insiders.

Danaher Stock Performance

NYSE:DHR opened at $206.83 on Wednesday. The stock has a market cap of $148.10 billion, a P/E ratio of 44.01, a PEG ratio of 2.82 and a beta of 0.77. The stock has a 50 day simple moving average of $196.69 and a 200 day simple moving average of $203.24. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $281.70.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping analysts’ consensus estimates of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%. The firm had revenue of $5.94 billion for the quarter, compared to analyst estimates of $5.83 billion. During the same quarter last year, the company earned $1.72 EPS. The company’s revenue was up 3.4% on a year-over-year basis. Research analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, July 25th. Shareholders of record on Friday, June 27th were paid a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.62%. Danaher’s dividend payout ratio (DPR) is presently 27.23%.

Analyst Ratings Changes

Several research analysts recently commented on the company. Royal Bank Of Canada reissued an “outperform” rating and set a $250.00 price target on shares of Danaher in a research report on Wednesday, April 23rd. Deutsche Bank Aktiengesellschaft reduced their price target on Danaher from $240.00 to $235.00 in a research report on Thursday, June 5th. Robert W. Baird increased their price target on Danaher from $225.00 to $226.00 and gave the company an “outperform” rating in a research report on Friday, July 18th. TD Cowen increased their price target on Danaher from $240.00 to $248.00 and gave the company a “buy” rating in a research report on Wednesday, April 23rd. Finally, Scotiabank raised Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 price target for the company in a research report on Friday, July 11th. Three equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Danaher has a consensus rating of “Moderate Buy” and a consensus target price of $247.61.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.